(7-chloro-4-methyl-quinazolin-2-yl)-guanidine | 37836-92-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (7-chloro-4-methyl-quinazolin-2-yl)-guanidine
• 英文别名: 2-(7-Chloro-4-methylquinazolin-2-yl)guanidine
• CAS: 37836-92-3
• 化学式: C₁₀H₁₀ClN₅
• 分子量: 235.676
• InChiKey: MVYMTIYXJWGXQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  90.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氯苯胺 在 盐酸 、 碘 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 0.17h， 生成 (7-chloro-4-methyl-quinazolin-2-yl)-guanidine
  参考文献：
  名称：

  Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure

  摘要：

  The heme enzyme myeloperoxidase (MPO) participates in innate immune defense mechanism through formation of microbicidal reactive oxidants. However, evidence has emerged that MPO-derived oxidants contribute to propagation of inflammatory diseases. Because of the deleterious effects of circulating MPO, there is a great interest in the development of new efficient and specific inhibitors. Here, we have performed a novel virtual screening procedure, depending on ligand-based pharmacophore modeling followed by structure-based virtual screening. Starting from a set of 727842 compounds, 28 molecules were selected by this virtual method and tested on MPO in vitro. Twelve out of 28 compounds were found to have an IC50 less than 5 mu M. The best inhibitors were 2-(7-methoxy-4-methylquinazolin-2-yl)guanidine (28) and (R)-2-(14(2,3-dihydro-1H-imidazol-2-yl-methyl)pyrrolidin-3-yl)-5-fluoro-1H-benzo[d]imidazole (42) with IC50 values of 44 and 50 nM, respectively. Studies on the mechanism of inhibition suggest that 28 is the first potent mechanism-based inhibitor and inhibits irreversibly MPO at nanomolar concentration.

  DOI：

  10.1021/acs.jmedchem.7b00285

文献信息

• [EN] QUINAZOLINE COMPOUNDS AS INHIBITORS OF PREMATURE TERMINATION CODONS<br/>[FR] COMPOSÉS DE QUINAZOLINE UTILISÉS EN TANT QU'INHIBITEURS DE CODONS STOP PRÉMATURÉS
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2021228945A1

  公开（公告）日：2021-11-18

  The present invention relates to the use of at least one compound of formula (I), or one of its pharmaceutically acceptable salts, for preventing and/or treating a disease caused by a nonsense mutation. It also relates to compounds of formula (II) and their uses.